VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

November 10, 2017 | Conferences, Glioblastoma ("GBM"), Press Releases

New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccine
Poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32^nd Annual Meeting on Friday, November 10^th

VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Catalina Soare, VBI’s head of preclinical development, will present new preclinical data demonstrating the potency of VBI-1901 as a therapeutic vaccine candidate against glioblastoma multiforme (GBM) at the 32^nd annual meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland, on November 10, 2017.

Dr. Soare will present preclinical data, which confirms the use of intradermal delivery of VBI’s enveloped virus-like particle (eVLP), VBI-1901, may be a potent “off-the-shelf” dendritic cell vaccine. Following intradermal injection of VBI-1901, migratory dendritic cells at the injection site were confirmed to stimulate potent, adaptive T-cell immunity.

The FDA recently accepted VBI’s IND for VBI-1901. The company expects to initiate enrollment in a multi-center Phase 1/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the fourth quarter of 2017.

Event Details

Event: Annual Meeting of the Society for Immunotherapy of Cancer
Date: Friday, November 10, 2017
Time: 12:30 PM – 2:00 PM EST; 6:30 PM – 8:00 PM EST
Location: Gaylord National Hotel & Convention Center, National Harbor, Maryland
Event Website: http://www.sitcancer.org/education/annualmeeting

GBM Program Background

Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than 16 months.

Targeted immunotherapy may provide a promising adjunct or alternative to conventional GBM treatment. Immunotherapy is a fundamentally different way of treating cancer that stimulates the patient’s immune system to resume its attack on tumors. While conventional therapies are non-specific and may damage surrounding normal tissues, targeted immunotherapy may offer a highly specific and potentially long-lasting treatment approach that leverages the immune system to protect against cancer.

Developing a broadly applicable GBM immunotherapy requires the identification of antigens that are consistently expressed on GBM tumor cells. Recent research has demonstrated that an anti-CMV dendritic cell vaccination regimen may extend overall survival in patients with GBM. Thus, effective targeting of CMV antigens may represent an attractive strategy for a GBM immunotherapy.

To learn more about VBI’s GBM immunotherapy program, visit: https://www.vbivaccines.com/gbm/

About VBI Vaccines

⌃

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
VBI Investor and Media Contact

⌃

Nicole Anderson
Director, Corporate Communications & IR
Phone: (617) 830-3031 x124
Email: info@vbivaccines.com
VBI Cautionary Statement on Forward-looking Information

⌃

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.